Our fundamental challenge is not simply to create the data. Rather, it is to collect and analyze it systematically. Doing so ...

Individuals with SCT have one copy of the gene associated with sickle cell ... Meharry Sickle Cell Disease Center of Excellence. "This review shows that any primary, secondary, or tertiary cause ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps ...

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

Sickle cell anaemia is a genetic blood disorder characterised by the production of an abnormal haemoglobin, known as haemoglobin S. Sickle cell disease changes the shape of blood cells into a crescent ...

The NHS is rolling out a “revolutionary” gene therapy which effectively cures agonising sickle cell disease. Sickle cell is the fastest growing genetic condition in the UK where red blood ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

A sickle cell disease “cure” is to be offered to NHS patients for the first time. The £1.65 million gene therapy called exa-cel, also known under the brand name Casgevy, uses a Nobel Prize ...

"Our Phase 1 study evaluating fostamatinib in patients with sickle cell disease is an opportunity ... for an additional 28 days if tolerated. The primary objective of the study is to evaluate ...